Monoclonal antibodies: A therapeutic option for the treatment of ophthalmic diseases of the eye posterior segment
dc.creator | Ayón Chang, Catalina | |
dc.creator | Castán, Daniel | |
dc.creator | Mora Carmona, Adrián | |
dc.creator | Naranjo, Dunia | |
dc.creator | Obando, Francini | |
dc.creator | Mora Román, Juan José | |
dc.date.accessioned | 2024-07-03T20:43:40Z | |
dc.date.available | 2024-07-03T20:43:40Z | |
dc.date.issued | 2022-08-31 | |
dc.description.abstract | The eye is an organ that allows us to observe the outside world. Pathologies of the eye's posterior segment, such as glaucoma, macular degeneration, diabetic retinopathy, uveitis, and retinoblastoma, cause vision loss. Traditional treatments consist of applying topical medications that do not penetrate properly or using high doses that generate adverse effects. Different laser surgeries stop the pathology's progression but do not allow visual improvement. So, an alternative is to use monoclonal antibodies, proteins produced by different processes that selectively bind to metabolites associated with diseases, reducing the adverse effects of traditional treatments and improving the application of the drug in the area. The two main molecular targets are TNF (adalimumab, infliximab, and certolizumab pegol) and VEGF (bevacizumab and ranibizumab); other possibilities are under investigation. | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones Farmacéuticas (INIFAR) | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Docencia::Salud::Facultad de Farmacia | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones Farmacéuticas (INIFAR) | es_ES |
dc.identifier.doi | 10.33084/bjop.v5i3.2095 | |
dc.identifier.issn | 2621-4814 | |
dc.identifier.uri | https://hdl.handle.net/10669/91689 | |
dc.language.iso | eng | es_ES |
dc.rights | acceso abierto | es_ES |
dc.source | Borneo Journal of Pharmacy, 5(3), 229-246 | es_ES |
dc.subject | eye | es_ES |
dc.subject | adversse effects | es_ES |
dc.subject | monoclonal antibody | es_ES |
dc.subject | intravitreal therapy | es_ES |
dc.subject | Posterior segment disease | es_ES |
dc.subject | ophthalmic diseases | es_ES |
dc.title | Monoclonal antibodies: A therapeutic option for the treatment of ophthalmic diseases of the eye posterior segment | es_ES |
dc.type | artículo de revisión | es_ES |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 3.5 KB
- Format:
- Item-specific license agreed upon to submission
- Description: